Yara Abdou, MD

This video details patient-reported outcomes from the DESTINY-Breast09 Phase 3 trial, comparing first-line treatments T-DXd + pertuzumab versus THP (taxane-based therapy) for HER2+ advanced/metastatic breast cancer.

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

The doctors recommend using endocrine therapy-based options first-line when possible, before considering chemotherapy or antibody-drug conjugates, in order to preserve quality of life; they note exceptions could include patients with rapid progression or visceral crisis where immediate chemotherapy may be warranted, and that determining optimal sequencing requires understanding the safety profiles and efficacy data for the available regimens.

The TROPION-Breast01 trial studied the antibody-drug conjugate datopotamab deruxtecan (Dato-DXd) in previously treated HR+, HER2- breast cancer patients and showed improved progression-free survival to 7 months compared to 4.5 months with standard chemotherapy, with less high grade toxicity observed with Dato-DXd.

The EMERALD study showed improved progression-free survival with elacestrant compared to standard endocrine therapy in patients with ESR1 mutations who progressed on prior AI and CDK4/6 inhibitors, with the greatest benefit in those having longer duration of response to first-line therapy.

Laura Huppert, MD, and Yara Abdou, MD, discuss the CAPItello-291 trial which looked at the efficacy of capivasertib, a small molecule AKT inhibitor, in combination with fulvestrant for patients with estrogen receptor positive, HER2 negative advanced breast cancer who had progressed on prior endocrine therapy.

Laura Huppert, MD, and Yara Abdou, MD, review approaches to repeat hormone receptor and HER2 status testing before initiating later lines of therapy in patients with metastatic breast cancer.

Laura Huppert, MD, and Yara Abdou, MD, discuss data from the MAINTAIN trial on ribociclib in combination with endocrine therapy in patients with metastatic breast cancer.

Laura Huppert, MD, and Yara Abdou, MD, provide an overview of the treatment landscape for HR+, HER2- advanced or metastatic breast cancer.

Experts provides an overview of HR-positive , HER2-negative metastatic breast cancer and current treatment approaches.

Yara Abdou, MD, discusses findings from the phase 2 MAINTAIN trial in patients with HER2-negative metastatic breast cancer, as well as the clinical implications of these trial results.

Yara Abdou, MD, discusses treatment sequencing with CDK4/6 inhibitors across all lines of therapy in patients with hormone receptor–positive, HER2-negative breast cancer.

Yara Abdou, MD, discusses the considerations between AKT inhibitors vs PI3K inhibition in patients with hormone receptor-positive, HER2-negative breast cancer.

Yara Abdou, MD, discusses updates in the treatment of patients with HR-positive, HER2-negative breast cancer.

Yara Abdou, MD, discusses racial disparities in breast cancer outcomes in patients enrolled to the phase 3 RxPONDER trial.

Yara Abdou, MD, discusses the significance of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

After discussing a few more key datasets from the SABCS 2021 Virtual Meeting, expert panelists discuss how they would approach treatment in several subsets of breast cancer.

Focusing on datasets from the SABCS 2021 Virtual Meeting, panelists consider novel approaches to the management of brain metastases in breast cancer.

Expert panelists share their perspectives on metastatic breast cancer management datasets from the SABCS 2021 Virtual Meeting.

Yara Abdou, MD, sheds light on the challenging path of becoming an oncologist.